Who
Carol Giltner Gallagher
Director
Company insider
Files Form 4 as: Director, TRex Bio; Director, PMV Pharmaceuticals; Director, Atara Biotherapeutics; Director, Mirati Therapeutics; Director, Frazier Lifesciences Acquisition; Director, Turning Point Therapeutics; Director, Certara; Director, Tempest Therapeutics.
In numbers
- Trades disclosed
- 150
- Buys
- 4
- Sells
- 18
- Bought
- $466K
- Sold
- $2.5M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 16 May 2007
- Last trade
- 8 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Oct 2026filed 8 Oct 2026 | TRXB TRex Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —42,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —42,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,828 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —33,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —33,500 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —67,500 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code G | —67,500 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 31 Mar 2024filed 2 Apr 2024 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code D | —12,784 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —7,555 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —6,808 | filing |
| 29 Dec 2023filed 3 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code A | $400K6,808 at $58.75 | filing |
| 14 Nov 2023filed 15 Nov 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Bought | $28K90,980 at $0.31 | filing |
News
No headline names them, or the companies they trade most, lately.